Nivolumab for malignant transformation of ovarian mature cystic teratoma

• DOI: 10.1016/j.gore.2022.101115
• Publication Date: 2022-12-10T16:29:01Z
• Authors: Kayoko Yoshimura; Koji Yamanoi; Masashi Kanai; Asuka Okunomiya; Yusuke Sagae; Masumi Sunada; Mana Taki; Masayo Ukita; Yoshitsugu Chigusa; Akihito Horie; Ken Yamaguchi; Junzo Hamanishi; Sachiko Minamiguchi; Noboru Yamamoto; Manabu Muto; Masaki Mandai
• Keywords: Malignant Transformation; Mature Cystic Teratoma

Mature cystic teratoma of the ovary (MCT) occasionally undergoes malignant transformation (MT) that is resistant to chemotherapy and has a poor prognosis. We experienced case clinically aggressive MCT-MT invades surrounding organs tissues. Although tumor was resected entirely, rapid recurrence occurred during postoperative (paclitaxel + ifosfamide cisplatin). The results comprehensive genomic profiling test performed early in period showed high mutational burden 23 mutations/Mb. Treatment with nivolumab monotherapy promptly been initiated very successful for more than one year.